These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Ding Y, Wang W, Feng M, Wang Y, Zhou J, Ding X, Zhou X, Liu C, Wang R, Zhang Q. Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990 [Abstract] [Full Text] [Related]
8. Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. Park J, Park J, Pei Y, Xu J, Yeo Y. Adv Drug Deliv Rev; 2016 Sep 01; 104():93-109. PubMed ID: 26686832 [Abstract] [Full Text] [Related]
9. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy. De Backer L, Cerrada A, Pérez-Gil J, De Smedt SC, Raemdonck K. J Control Release; 2015 Dec 28; 220(Pt B):642-50. PubMed ID: 26363301 [Abstract] [Full Text] [Related]
10. Role of integrated cancer nanomedicine in overcoming drug resistance. Iyer AK, Singh A, Ganta S, Amiji MM. Adv Drug Deliv Rev; 2013 Nov 28; 65(13-14):1784-802. PubMed ID: 23880506 [Abstract] [Full Text] [Related]
11. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma. Huang KW, Lai YT, Chern GJ, Huang SF, Tsai CL, Sung YC, Chiang CC, Hwang PB, Ho TL, Huang RL, Shiue TY, Chen Y, Wang SK. Biomacromolecules; 2018 Jun 11; 19(6):2330-2339. PubMed ID: 29808997 [Abstract] [Full Text] [Related]
13. Sphk2 RNAi nanoparticles suppress tumor growth via downregulating cancer cell derived exosomal microRNA. Liang J, Zhang X, He S, Miao Y, Wu N, Li J, Gan Y. J Control Release; 2018 Sep 28; 286():348-357. PubMed ID: 30077738 [Abstract] [Full Text] [Related]
14. Lipid Nanoparticle Systems for Enabling Gene Therapies. Cullis PR, Hope MJ. Mol Ther; 2017 Jul 05; 25(7):1467-1475. PubMed ID: 28412170 [Abstract] [Full Text] [Related]
16. Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. Wang K, Kievit FM, Sham JG, Jeon M, Stephen ZR, Bakthavatsalam A, Park JO, Zhang M. Small; 2016 Jan 27; 12(4):477-87. PubMed ID: 26641029 [Abstract] [Full Text] [Related]
17. Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems. Yan JJ, Liao JZ, Lin JS, He XX. Tumour Biol; 2015 Jan 27; 36(1):55-67. PubMed ID: 25424700 [Abstract] [Full Text] [Related]
18. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. Turato C, Balasso A, Carloni V, Tiribelli C, Mastrotto F, Mazzocca A, Pontisso P. J Control Release; 2017 Dec 28; 268():184-197. PubMed ID: 29051062 [Abstract] [Full Text] [Related]
19. Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review. Varshosaz J, Taymouri S. Curr Pharm Des; 2015 Dec 28; 21(29):4310-28. PubMed ID: 26323421 [Abstract] [Full Text] [Related]
20. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand. Lee DJ, Kessel E, Edinger D, He D, Klein PM, Voith von Voithenberg L, Lamb DC, Lächelt U, Lehto T, Wagner E. Biomaterials; 2016 Jan 28; 77():98-110. PubMed ID: 26584350 [Abstract] [Full Text] [Related] Page: [Next] [New Search]